Summary PHI FPX3200 Assessment2 1.docx Running head: EXPANDING ACCESS TO EARLY-STAGE TRIA1 L DRUGS PHI-FPX3200 Expanding Access to Early-Stage Trial Drugs PHI-FPX3200: Ethics in Health Care Capella University Expanded Access and Compassionate Use Program

PHI FPX3200 Assessment2 Running head: EXPANDING ACCESS TO EARLY-STAGE TRIA1 L DRUGS PHI-FPX3200 Expanding Access to Early-Stage Trial Drugs PHI-FPX3200: Ethics in Health Care Capella University Expanded Access and Compassionate Use Programs Throughout the history of medicine, the use of experimental drugs and procedures has led to significant medical advancements capable of curing or prolonging the life of terminally-ill patients. Since clinical testing must complete various testing phases and may take years to reach market approval, many terminally-ill patients may not live long enough to benefit from the newly-developed drugs (Raus, 2016). These patients, who possibly have no other options with regard to treatment, may choose to serve as test subjects in randomized controlled trials with the goal of finding a remedy for their ailment or to benefit future patients diagnosed with the same condition. Whil